| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/17/2001 | CA2391277A1 Treating cancer by increasing intracellular malonyl coa levels |
| 05/17/2001 | CA2391230A1 Heterocycle substituted diphenyl leukotriene antagonists |
| 05/17/2001 | CA2391129A1 Lentiviral vector transduction of hematopoietic stem cells |
| 05/17/2001 | CA2390975A1 Potentiation of prodrug efficacy |
| 05/17/2001 | CA2390932A1 Body weight gain inhibitors |
| 05/17/2001 | CA2390928A1 Alkoxyiminoalkanoic acid derivatives |
| 05/17/2001 | CA2390919A1 Nose drop containing condensed pyridazine |
| 05/17/2001 | CA2390880A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 05/17/2001 | CA2390797A1 Methods for the treatment and prevention of neurodegenerative conditions |
| 05/17/2001 | CA2390789A1 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | CA2390655A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 05/17/2001 | CA2390561A1 Use of an aldosterone antagonist for treating restenosis |
| 05/17/2001 | CA2390557A1 Solid preparations for oral use |
| 05/17/2001 | CA2390553A1 Pharmaceutical formulations comprising labdanes for the treatment of tumors or leukemias |
| 05/17/2001 | CA2390531A1 ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders |
| 05/17/2001 | CA2390530A1 N-aryl-(homopiperazinyl)-cyclohexyl amines as 5-ht transporters |
| 05/17/2001 | CA2390524A1 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity |
| 05/17/2001 | CA2390510A1 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
| 05/17/2001 | CA2390501A1 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 05/17/2001 | CA2390496A1 Polycycloalkylpurines as adenosine receptor antagonists |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2390376A1 .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis |
| 05/17/2001 | CA2390374A1 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | CA2390276A1 Novel compounds to treat diabetes and associated conditions |
| 05/17/2001 | CA2390231A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 05/17/2001 | CA2390161A1 Methods for identifying and using amyloid-inhibitory compounds |
| 05/17/2001 | CA2390128A1 Pharmaceutical formulation |
| 05/17/2001 | CA2390101A1 A method of treating substance addiction |
| 05/17/2001 | CA2389724A1 28 human secreted proteins |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389550A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/17/2001 | CA2389524A1 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2389305A1 28 human secreted proteins |
| 05/17/2001 | CA2389193A1 Hydromorphone compositions and methods of their synthesis |
| 05/17/2001 | CA2389176A1 A method and composition for treating prostate cancer |
| 05/17/2001 | CA2389041A1 Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or .beta.-sheet rich pathological precursor thereof |
| 05/17/2001 | CA2388918A1 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 05/17/2001 | CA2388914A1 15 human secreted proteins |
| 05/17/2001 | CA2388912A1 6 human secreted proteins |
| 05/17/2001 | CA2388729A1 Imidazopyridine derivatives as phosphodiesterase vii inhibitors |
| 05/17/2001 | CA2388644A1 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| 05/17/2001 | CA2388593A1 Bicyclic and tricyclic heteroaromatic compounds |
| 05/17/2001 | CA2388343A1 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 05/17/2001 | CA2388044A1 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
| 05/17/2001 | CA2388030A1 Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders |
| 05/17/2001 | CA2388019A1 24 human secreted proteins |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387964A1 22 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | CA2387089A1 Interferon gamma for the treatment of asthma |
| 05/17/2001 | CA2386878A1 Lipoxin a4 and its analogs for the treatment of dry eye |
| 05/17/2001 | CA2386876A1 Combination chemotherapy |
| 05/17/2001 | CA2386636A1 15-hydroxyeicosatetraenoic acid-related compounds and methods of use |
| 05/17/2001 | CA2386632A1 Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye |
| 05/17/2001 | CA2386623A1 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
| 05/17/2001 | CA2386619A1 Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| 05/17/2001 | CA2386333A1 3-heteroatom substituted and two carbon homologs 15-hete and methods of use |
| 05/17/2001 | CA2382676A1 Prevention of plaque rupture by acat inhibitors |
| 05/17/2001 | CA2361139A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
| 05/17/2001 | CA2325226A1 Use of polypeptides or nucleic acids encoding these for the diagnosis or treatment of skin disorders, and their use for the identification of pharmacologically active substances |
| 05/16/2001 | EP1099706A2 Estrane sulphamate derivatives as steroid sulphatase inhibitors |
| 05/16/2001 | EP1099702A1 Substituted morpholine derivatives and their use as therapeutic agents |
| 05/16/2001 | EP1099701A1 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B |
| 05/16/2001 | EP1099700A1 Crystalline oxathiolane derivatives |
| 05/16/2001 | EP1099695A1 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them |
| 05/16/2001 | EP1099692A1 N,n-substituted cyclic amine derivatives |
| 05/16/2001 | EP1099446A2 Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent |
| 05/16/2001 | EP1099444A1 Gastric acid secretion |
| 05/16/2001 | EP1099442A2 Methods of administering apo B-secretion/MTP inhibitors |
| 05/16/2001 | EP1099441A2 Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof |
| 05/16/2001 | EP1099440A1 Therapeutic agents |
| 05/16/2001 | EP1099439A2 Use of apo B secretion/MTP inhibitors |
| 05/16/2001 | EP1099438A2 Use of APO B secretion/MTP inhibitors |
| 05/16/2001 | EP1098986A2 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe) |
| 05/16/2001 | EP1098985A1 Genes of the dead box protein family, their expression products and use |
| 05/16/2001 | EP1098970A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors |
| 05/16/2001 | EP1098969A2 Use of nucleic acid molecules as antiviral agents |
| 05/16/2001 | EP1098966A1 Methods for purifying nucleic acids |
| 05/16/2001 | EP1098931A1 Polyionic hydrogels based on xanthan and chitosan for stabilising and controlled release of vitamins |
| 05/16/2001 | EP1098901A1 Novel 6-deoxy erythromycin derivatives, method for preparing same and use as medicines |
| 05/16/2001 | EP1098898A1 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3- (4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate |
| 05/16/2001 | EP1098897A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 05/16/2001 | EP1098896A1 5-bicycloindole compounds |
| 05/16/2001 | EP1098894A1 Fkbp inhibitors |
| 05/16/2001 | EP1098893A1 Cyclic compounds useful in the treatment of dyslipidemia, atherosclerosis and diabetes, pharmaceutical compositions and preparation process |
| 05/16/2001 | EP1098892A1 Biphenyl derivatives |
| 05/16/2001 | EP1098891A1 Polycyclic thiazolidin-2-ylidene amines, method for the production and use thereof as medicaments |
| 05/16/2001 | EP1098889A1 Substituted piperazones and their therapeutic uses |
| 05/16/2001 | EP1098888A1 Piperazinone derivatives and their uses |
| 05/16/2001 | EP1098886A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors |
| 05/16/2001 | EP1098885A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 05/16/2001 | EP1098884A1 Il-8 receptor antagonists |
| 05/16/2001 | EP1098878A1 Bispiperidines as antithrombotic agents |
| 05/16/2001 | EP1098877A1 Derivatized polymers of alpha-olefin-maleic anhydride alkyl half-ester or full acid |
| 05/16/2001 | EP1098874A1 Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments |
| 05/16/2001 | EP1098873A1 Alpha-(2-hydroxyphenyl)nitrone compounds, pharmaceutical compositons containing the same and their use for treating inflammation |
| 05/16/2001 | EP1098871A1 $g(a)-AMINO ACID PHENYL ESTER DERIVATIVES |
| 05/16/2001 | EP1098870A2 Nitric esters and nitrate salts of specific drugs |